Abstract
Bone marrow-derived mesenchymal stem cells (BMSCs) exert protective effects against pulmonary ischemia/reperfusion (I/R) injury; however, the potential mechanism involved in their protective ability remains unclear. Thus, this study aimed to explore the function and underlying mechanism of BMSC-derived exosomal lncRNA-ZFAS1 in pulmonary I/R injury. Pulmonary I/R injury models were established in mice and hypoxia/reoxygenation (H/R)-exposed primary mouse lung microvascular endothelial cells (LMECs). Exosomes were extracted from BMSCs. Target molecule expression was assessed by qRT-PCR and Western blotting. Pathological changes in the lungs, pulmonary edema, apoptosis, pro-inflammatory cytokine levels, SOD, MPO activities, and MDA level were measured. The proliferation, apoptosis, and migration of LMECs were detected by CCK-8, EdU staining, flow cytometry, and scratch assay. Dual-luciferase reporter assay, RNA pull-down, RIP, and ChIP assays were performed to validate the molecular interaction. In the mouse model of pulmonary I/R injury, BMSC-Exos treatment relieved lung pathological injury, reduced lung W/D weight ratio, and restrained apoptosis and inflammation, whereas exosomal ZFAS1 silencing abolished these beneficial effects. In addition, the proliferation, migration inhibition, apoptosis, and inflammation in H/R-exposed LMECs were repressed by BMSC-derived exosomal ZFAS1. Mechanistically, ZFAS1 contributed to FOXD1 mRNA decay via interaction with UPF1, thereby leading to Gal-3 inactivation. Furthermore, FOXD1 depletion strengthened the weakened protective effect of ZFAS1-silenced BMSC-Exos on pulmonary I/R injury. ZFAS1 delivered by BMSC-Exos results in FOXD1 mRNA decay and subsequent Gal-3 inactivation via direct interaction with UPF1, thereby attenuating pulmonary I/R injury.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Lung ischemia and succeeding reperfusion refer to pulmonary ischemia/reperfusion (I/R) injury, which occurs during many clinical events, including heart or lung transplantation, cardiopulmonary bypass surgery, and pulmonary thrombolysis [1]. Pulmonary I/R injury remains a serious problem that induces primary graft dysfunction, which has been considered as a primary cause of death after lung transplantation [1, 2]. In addition, pulmonary I/R injury results in the overproduction of reactive oxygen species, thereby causing direct endothelial cell injury, apoptosis, and inflammatory response [3]. Recent studies have reported multiple treatment strategies to limit pulmonary I/R injury, such as anti-oxidant strategies, anti-inflammatory strategies, gaseous molecular ventilation, and application of mesenchymal stem cells (MSCs) [4]. Despite extensive study, the exact pathological mechanism of pulmonary I/R injury remains unclear, and a satisfactory treatment is not yet available. Therefore, uncovering the potential molecular mechanism of pulmonary I/R injury is essential to develop novel effective clinical interventions.
Growing evidence has demonstrated the protective effect of MSCs against lung injury after lung transplantation [5, 6]. MSCs induce protection against lung injury by releasing many paracrine factors that inhibit apoptosis, inflammation, and epithelial and endothelial leakage [5]. In addition, exosomes released by MSCs play a crucial role in the therapeutic efficacy of MSCs during myocardial repair [7]. Exosomes are small membrane vesicles of 30–150 nm length, which mediate the intercellular communication by delivering functional proteins and RNAs [8]. Previous reports have suggested that bone marrow-derived MSC exosomes (BMSC-Exos) relieved pulmonary I/R injury [9, 10], which possessed similar physiological functions to BMSCs. Notably, exosomes have distinct advantages over MSCs because of the absence of immune rejection [8], indicating that BMSC-Exos have a broader application potential than BMSCs after lung transplantation. However, the protective mechanism of BMSC-Exos underlying pulmonary I/R injury remains unknown.
Long non-coding RNAs (lncRNAs) are RNA transcripts composed of more than 200 nucleotides without coding capacity, which participate in multiple pathophysiologic processes such as cell differentiation, growth, inflammation, neuronal differentiation, or cancer development through different mechanisms of gene regulation [11,12,13]. For example, lncRNA X-inactive-specific transcript was reported to be involved in acute lung injury after lung transplantation via sponging miR-21 [14]. A recent study has indicated that lncRNA zinc finger antisense 1 (ZFAS1) could attenuate septic lung injury via repressing inflammation [15], indicating the application potential of ZFAS1 in relieving pulmonary I/R injury. Recently, the exosome-mediated delivery of ZFAS1 has been reported to play a pivotal role in various disorders. For example, exosomal ZFAS1 has been demonstrated to facilitate gastric cancer progression [16]. To date, whether BMSC-Exos can alleviate pulmonary I/R injury via transferring ZFAS1 remains unclear and deserves further investigation.
A growing body of research has illustrated that lncRNAs post‐transcriptionally modulate gene expression via interacting with RNA-binding proteins (RBPs) to mediate mRNA decay. For example, lncRNA maternally expressed gene 3 interacted with polypyrimidine tract-binding protein 1 (PTBP1) to induce Shp mRNA decay, which caused cholestatic liver injury [17]. Up-frameshift 1 (UPF1) has been identified as a key modulator of RNA decay [18]. Forkhead box D1 (FOXD1), a transcription factor, has been reported to drive the progression of lung cancer via interacting with galectin-3 (Gal-3) [19]. Nevertheless, the functional role of the FOXD1/Gal-3 axis in pulmonary I/R injury has not been documented. Interestingly, the Starbase database (https://starbase.sysu.edu.cn/index.php) has predicted that ZFAS1 and FOXD1 could bind to UPF1. Thus, we hypothesized that MSC-derived exosomal ZFAS1 reduced FOXD1 mRNA stability via interacting with UPF1 and subsequently inactivated Gal-3, thereby conferring protection against pulmonary I/R injury.
In this work, we found that BMSC-derived exosomes mitigated pulmonary I/R injury via delivering ZFAS1. Mechanistically, ZFAS1 interacted with UPF1 to trigger FOXD1 mRNA decay and succeeding Gal-3 inactivation. Our findings will provide insights into the novel mechanism of exosomal ZFAS1 in pulmonary I/R injury and identify BMSC-derived exosomal ZFAS1 as an effective intervention.
Materials and Methods
Cell Culture and Identification
BMSCs were isolated from the femurs and tibias of male and female C57BL/6 mice (8 weeks old) as described previously [20]. In brief, the bone marrow was extracted and washed with Dulbecco’s modified eagle medium (DMEM, catalog number: D5796, Sigma-Aldrich, USA) several times. After filtration and centrifugation, the isolated BMSCs were maintained in DMEM supplemented with 10% fetal bovine serum (FBS, catalog number: 10100147, Gibco, USA). For the identification of BMSCs, the positive expression of CD105, CD90, and CD73 and negative expression of human leukocyte antigen DR (HLA-DR) and CD45 were validated using flow cytometry. A pool of BMSCs from different mice was constructed and used in this study. HEK293 cells obtained from American Type Culture Collection (USA) were maintained in DMEM/F12 (catalog number: D0697, Sigma-Aldrich) with 10% FBS and placed in a humidified incubator with 5% CO2.
Exosome Isolation and Quantification
BMSC-Exos were extracted from the cell culture supernatant of isolated mouse BMSCs as described previously [21]. In brief, BMSCs with 80% confluency were maintained in a serum-free medium for 24 h, and then, the supernatant was obtained. After filtering through a 0.22-μm filter, the collected supernatant was centrifuged at 2000 g for 30 min at 4 °C, followed by ultracentrifugation at 10,000 g for 30 min at 4 °C to remove non-exosome vesicles and at 100,000 g for 4 h at 4 °C to pellet the exosomes. BMSC-Exos were re-suspended in ice-cold phosphate-buffered saline (PBS) and stored at − 80 °C for further experiments. BMSC-Exos were observed under a transmission electron microscope. NanoSight nanoparticle tracking analysis (NTA) was used to analyze the BMSC-Exo size. Surface antigens of exosomes (CD63, CD9, tumor susceptibility gene 101 [TSG101], and heat shock protein [Hsp70]) and endoplasmic reticulum marker (Calnexin) was assessed by Western blotting.
Isolation of Primary Mouse Lung Microvascular Endothelial Cells (LMECs) and Exposure to Hypoxia/Reoxygenation (H/R)
LMECs were isolated from male and female C57BL/6 mice (8 weeks old) in accordance with a previous study [22]. In brief, after euthanasia, the lungs were collected from mice. After removing large airways and mincing, the lung tissues were digested with 1 mg/mL of collagenase (catalog number: COLLDISP-RO, Sigma-Aldrich). The digested cells were filtered, centrifugated, and maintained in DMEM containing 20% FBS, 150 μg/mL of endothelial cell growth supplement (catalog number: 211F-GS, Sigma-Aldrich), and 100 μg/mL of penicillin/streptomycin (catalog number: V900929, Sigma-Aldrich). We constructed a pool of LMECs from different mice. LMECs between passages 2 and 10 were adopted in this study. LMECs were exposed to H/R to mimic the pulmonary I/R injury in vitro. Hence, LMECs were maintained in a hypoxic chamber containing 95% N2-5% CO2 for 3 h, followed by culture in a normoxic chamber for 1 h [23].
PKH-26 Staining
In evaluating the uptake of BMSC-Exos by LMECs, BMSC-Exos were stained with PKH-26 (catalog number: MINI26-1KT, Sigma-Aldrich) and then added to LMECs. After incubation for 24 h, the nuclei were stained with 4′-6-diamidino-2-phenylindole (DAPI, catalog number: D9542, Sigma-Aldrich) and observed under a fluorescence microscope (Olympus, Tokyo, Japan) at a magnification of 400 × .
Lentivirus Infection
Lentiviruses carrying negative control shRNA (shNC), sh-ZFAS1 (gene ID: NR_138563.1), sh-FOXD1 (gene ID: NM_008242.2), sh-UPF1 (gene ID: NM_001122829.2), sh-Gal-3 (gene ID: NM_001145953.1), and genes for ZFAS1, FOXD1, and Gal-3 were provided by GeneChem (Shanghai, China). The sequences for shRNAs were as follows: sh-ZFAS1, 5′-GGTTAACTTGCAGATGGTTGA-3′; sh-FOXD1, 5′-CGTATATCGCGCTCATCACTA-3′; sh-UPF1, 5′-GGAGTCACAGACTCAAGATAA-3′; sh-Gal-3, 5′-GCAGTACAACCATCGGATGAA-3′. BMSCs were infected with lentiviruses carrying shNC, sh-ZFAS1, or genes for ZFAS1. On the contrary, LMECs were infected with lentiviruses carrying shNC, sh-FOXD1, sh-UPF1, sh-Gal-3, and genes for FOXD1. Moreover, Gal-3 was supplemented with 5 μg/mL of polybrene (catalog number: TR-1003-G, Sigma-Aldrich). After infection for 48 h, the infected GFP-positive cells were observed under a fluorescent microscope and selected using 15 μg/mL of puromycin (catalog number: 60209ES, Yeasen, Shanghai, China).
Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated from lung tissues or LMECs using a Trizol reagent (catalog number: 15596018, Thermo Fisher). Complementary DNA was synthesized using the Hifair® II 1st-strand cDNA synthesis kit (catalog number: 11119ES60, Yeasen). Quantitative PCR was performed using the Hieff® qPCR SYBR Green Master Mix (catalog number: 11201ES03. Yeasen). Gene expression normalized to GAPDH was calculated using the 2−△△Ct method. The primer sequences are listed in Table 1. The experiment was repeated three times.
Western Blotting
Total proteins were extracted using the RIPA buffer (catalog number: 89901, Thermo Fisher), and protein concentration was determined using the BCA protein quantification kit (catalog number: 20201ES76. Yeasen). Protein samples (30 μg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to polyvinylidenedifluoride membranes. The membranes were blocked with 1% bovine serum albumin and probed with primary antibodies against Calnexin (1:1000, ab133615, Abcam, UK), CD63 (1:1000, ab217345, Abcam), CD9 (1:1000, 98,327, CST, USA), TSG101 (1:1000, ab125011, Abcam), HSP70 (1:1000, 4872, CST), FOXD1 (1:500, bs-12193R, Bioss, Beijing, China), Gal-3 (1:1000, ab76245, Abcam), UPF1 (1:1000, 12,040, CST), and GAPDH (1:2500, ab8245, Abcam) at 4 °C overnight. After incubation with a peroxidase-conjugated secondary antibody, the protein bands were detected by enhanced chemiluminescence (catalog number: 32106, Pierce, USA). The experiment was repeated three times.
Cell Viability Detection
LMEC viability was assessed using the cell counting kit 8 (CCK-8, catalog number: 40203ES60, Yeasen). LMECs from different treatment groups were plated into 96-well plates at a density of 3000 cells per well and then reacted with CCK-8 solution (10 μL) for 3 h at 37 °C. The results were detected at 450 nm on a microplate reader (Tecan, Switzerland). The experiment was repeated three times.
5-Ethynyl-2′-Deoxyuridine (EdU) Staining
EdU staining was performed to measure the proliferation of LMECs using the EdU Apollo567 in vitro kit (catalog number: CA1170, Solarbio, Beijing, China). In brief, LMECs were labeled with 50 µM of EdU solution for 2 h. After fixation in 4% formaldehyde (catalog number: F8775, Sigma-Aldrich), LMECs were added with 2 mg/mL of glycine (catalog number: G7126, Sigma-Aldrich), followed by incubation with Apollo staining buffer. Subsequently, LMECs were treated with 0.5% TritonX-100 (catalog number: T8787, Sigma-Aldrich) and stained with DAPI (catalog number: D9542, Sigma-Aldrich). Images were captured using a fluorescence microscope (Olympus, Tokyo, Japan) at a magnification of 100 × . The experiment was repeated three times.
Cell apoptosis assay
LMEC apoptosis was measured using the Annexin V-FITC apoptosis detection kit (catalog number: CA1020, Solarbio). The collected LMECs were stained with 5 µL of Annexin V/FITC for 5 min in the dark and then with 5 µL PI solution. Finally, the samples were immediately analyzed using flow cytometry. The experiment was repeated three times.
Scratch Assay
LMECs were plated in six-well plates. After reaching 100% confluence, a scratch with an equal width was generated using a pipette tip. LMECs were maintained in a serum-free medium for 24 h. After the scratch, the images were captured at 0 and 24 h using a light microscope at a magnification of 100 × . The experiment was repeated three times.
RNA Pull-Down
The biotinylated ZFAS1 probe and Oligo probe were purchased from RiboBio (Guangzhou, China) and added to the prepared protein extract, followed by incubation with streptavidin‐labeled magnetic beads to separate RNA–protein complexes. After elution, the retrieved UPF1 protein bound to ZFAS1 was measured by Western blotting. The experiment was repeated three times.
RNA Immunoprecipitation (RIP) Assay
The interaction between UPF1 and ZFAS1/FOXD1 was validated by RIP assay using the Magna RIP™ RNA-binding protein immunoprecipitation kit (catalog number: 17–700, Millipore, USA). LMEC lysates were incubated with magnetic beads conjugated with anti-UPF1 (12,040, Cell Signaling Technology) or anti-IgG (negative control, #3900, Cell Signaling Technology) antibodies. The levels of ZFAS1 or FOXD1 in co-precipitated RNAs were assessed by qRT-PCR. The experiment was repeated three times.
Chromatin Immunoprecipitation (ChIP)
The direct binding of FOXD1 to Gal-3 promotor (binding sequences: ATAAACAT) was validated by ChIP using the ChIP assay kit (catalog number: P2078, Beyotime, Haimen, China). In brief, LMECs were cross-linked with formaldehyde and subjected to ultrasonication to produce 200–1000 bp DNA fragments. Afterward, 50 μg of DNA fragments was immunoprecipitated with protein A/G beads conjugated with anti-FOXD1 (sc-293238, Santa Cruz, USA) or anti-IgG (#3900, Cell Signaling Technology) antibodies. The immunoprecipitated DNAs were extracted, purified, and detected by DNA agarose electrophoresis. The experiment was repeated three times.
Dual-Luciferase Reporter Assay
Gal-3 promoter sequences containing FOXD1-binding sites were inserted into a pGL3 vector (catalog number: E1751 Promega, USA). HEK293 cells were transfected with the pGL3-Gal-3 plasmid and sh-FOXD1/shnc or FOXD1 overexpression plasmid/vector using Lipofectamine 2000 (catalog number: 11668019, Thermo Fisher) according to the manufacturer’s instructions. After incubation for 24 h, the HEK293 cells were measured using the dual-luciferase reporter assay system (catalog number: E1910, Promega). The experiment was repeated three times.
Animal Models
Male C57BL/6 mice (8–10 weeks old) were obtained from SLAC Jingda Laboratory Animal Co., Ltd. (Hunan, China), and randomly divided into the following experimental groups (n = 6 per group): sham, I/R, I/R + PBS, I/R + MSC-Exos, I/R + Exos-shNC, I/R + Exos-shZFAS1, I/R + Exos-shZFAS1 + shNC, I/R + Exos-shZFAS1 + shFOXD1, and I/R + Exos-shZFAS1 + sh-Gal-3. Pulmonary I/R injury was induced in mice as previously reported [24]. All mice were subjected to anesthesia via intraperitoneal injection of 60 mg/kg pentobarbital sodium and then left anterolateral thoracotomy. The left pulmonary hilum of mice in I/R groups was blocked using a microvascular clamp for 1 h, and then, reperfusion was performed for 2 h by removing the clamp. The same operation procedure was performed in sham mice without blocking the left pulmonary hilum. Exosomes were administered to mice through intratracheal instillation in 30 μL of PBS at 24 h before the operation. Lentiviruses containing shFOXD1, sh-Gal-3, or shNC (1 × 108 PFUs in 30 μL of PBS, GeneChem) were administered via intratracheal instillation 1 week before the induction of pulmonary I/R injury. Heating pads were placed on mice during experimental procedures to maintain body temperature. The lungs were harvested from mice that were euthanatized by overdose of sodium pentobarbital. All experimental procedures were approved by the Animal Care and Use Committee of the Third Affiliated Hospital of Soochow University.
Lung Wet/Dry (W/D) Weight Ratio
The collected lungs were immediately weighed to obtain the wet weight. After drying for 2 days at 80 °C, the dry weight was measured. Finally, the W/D weight ratio was calculated.
Hematoxylin and Eosin (H&E) Staining
The collected lungs of mice were fixed in 4% paraformaldehyde, followed by paraffin embedding and cutting into 5-μm slices. H&E staining was performed using a commercial HE staining kit (catalog number: AR1180-100, Boster, Wuhan, China) following the protocol. The severity of lung injury was evaluated on the basis of the injury scores as previously described [25].
Measurement of Myeloperoxidase (MPO), Superoxide Dismutase (SOD), and Malondialdehyde (MDA) Levels
The activities of MPO, SOD, and MDA in lung tissues were assessed using the mouse myeloperoxidase ELISA kit (ab275109, Abcam), the superoxide dismutase activity assay kit (ab65354, Abcam), and the lipid peroxidation (MDA) assay kit (ab118970, Abcam), respectively, following the manufacturers’ protocols.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End-Labeling (TUNEL)
Apoptosis in lung slices was detected using the TUNEL assay kit (ab206386, Abcam). In brief, the slices were permeabilized using the proteinase K solution (catalog number: 1.07393, Sigma-Aldrich) for 20 min and blocked in 3% H2O (catalog number: W4502, Sigma-Aldrich), followed by incubation with TdT labeling reaction mix for 90 min. After incubation with stop buffer for 15 min, the slices were developed using DAB solution. Finally, the slices were observed under a light microscope (Olympus, Tokyo, Japan) at a magnification of 100 × .
Statistical Analysis
Data were collected from at least three independent experiments and expressed as mean ± standard deviation. Statistical analysis was performed using SPSS17.0. Differences were tested using Student’s t-test for two groups or one-way analysis of variance (ANOVA), followed by log-rank test for more than two groups. P < 0.05 was considered statistical significant.
Results
Characterization of BMSCs and Their Exosomes
Under a light microscope, we observed that mouse BMSCs were spindle shaped (Fig. 1A). In addition, the expression levels of cell surface antigens were assessed by flow cytometry. CD105, CD90, and CD73 showed a positive expression, whereas HLA-DR and CD45 showed a negative expression (Fig. 1B), thereby indicating the successful isolation of BMSCs. Subsequently, exosomes were isolated from mouse BMSCs and characterized using a transmission electron microscope. As shown in Fig. 1C, the extracted exosomes show a round or cup-like shape (Fig. 1C). NTA technology indicated that the diameter of isolated exosomes was 30–150 nM (Fig. 1D). Moreover, the positive expression of CD63, CD9, TSG101, and HSP70 and the negative expression of Calnexin in exosomes were validated by Western blotting (Fig. 1E). Therefore, exosomes were successfully extracted from mouse BMSCs.
BMSC-Derived Exosomes Relieve Pulmonary I/R Injury in Mice
In determining whether BMSC-Exos could attenuate pulmonary I/R injury, mice were administered with BMSC-Exos 24 h before lung I/R injury. We found that all mice survived after pulmonary I/R injury. Treatment with BMSC-Exos alleviated the I/R injury-induced disorder structure of pulmonary tissue and inflammatory infiltration (Fig. 2A). The enhanced lung injury score in the pulmonary I/R injury group was reduced after administration of BMSC-Exos (Fig. 2B). In addition, pulmonary edema as evidenced by an increase in lung W/D weight ratio in mice with pulmonary I/R injury was weakened by BMSC-Exo treatment (Fig. 2C). Moreover, apoptosis was triggered by pulmonary I/R injury in lung tissues, but BMSC-Exo treatment effectively restrained apoptosis (Fig. 2D). Furthermore, I/R injury significantly increased MPO and MDA levels but reduced SOD activity in the lungs, which were reversed by the delivery of BMSC-Exos (Fig. 2E–G). We also observed amplified lung inflammation in the I/R group based on the upregulation of TNF-α, IL-1β, and IL-6. However, the administration of BMSC-Exos effectively reduced the levels of these pro-inflammatory cytokines (Fig. 2H–J). Interestingly, the ZFAS1 level was reduced, whereas FOXD1 and Gal-3 levels were increased in the lungs in response to lung I/R stimulation. On the contrary, these changes were reversed after treatment with BMSC-Exos (Fig. 2K–L). These observations indicated that BMSC-Exos relieved pulmonary I/R injury in mice, and ZFAS1, FOXD1, and Gal-3 might be involved in the beneficial effect mechanism of BMSC-Exos.
BMSC-Derived Exosomes Induce Protection Against Pulmonary I/R Injury via Delivering lncRNA ZFAS1
Given that BMSC-Exos enhanced ZFAS1 expression in a pulmonary I/R injury model, we further explored the role of ZFAS1 in BMSC-Exos-mediated protection against pulmonary I/R injury. Thus, exosomes were isolated from BMSCs infected with lentiviruses carrying shZFAS1 or shNC. The silencing efficiency of ZFAS1 in BMSCs and BMSC-Exos was validated by qRT-PCR (Fig. 3A). H&E staining showed that BMSC-Exos-mediated attenuation in pathological changes of lung tissues was counteracted by exosomal ZFAS1 silencing (Fig. 3B and C). Moreover, compared with the BMSC-Exos-shNC group, the lung W/D weight ratio in the BMSC-Exos-shZFAS1 group was remarkably higher (Fig. 3D). The inhibitory effect of BMSC-Exos on apoptosis in lung tissues could be abolished by the knockdown of ZFAS1 in BMSC-Exos (Fig. 3E). Furthermore, the depletion of ZFAS1 in BMSC-Exos reversed the reduced MPO and MDA levels and increased SOD activity in BMSC-Exos-treated lung tissues (Fig. 3F–H). In addition, BMSC-Exos-induced inhibition in inflammatory cytokine release could be abrogated when BMSC-Exos-derived exosomal ZFAS1 was silenced (Fig. 3I–K). The high expression of ZFAS1 and low expression of FOXD1 and Gal-3 in the lungs of the BMSC-Exos-shNC group could be reversed in the BMSC-Exos-shZFAS1 group (Fig. 3L and M). Collectively, these results indicated that BMSC-Exos relieved pulmonary I/R injury via transferring ZFAS1.
BMSC-Derived Exosomal ZFAS1 Regulates the Proliferation, Apoptosis, and Migration of LMECs
In validating the protective effects of BMSC-derived exosomal ZFAS1 in vitro, LMECs were exposed to H/R to simulate pulmonary I/R injury. The overexpression efficiency of ZFAS1 in BMSCs and BMSC-Exos was confirmed by qRT-PCR (Fig. 4A). Exosomes were isolated from BMSCs infected with lentiviruses carrying shZFAS1, shNC, vector, or ZFAS1. After incubation with BMSC-Exos, the uptake of PKH26-labeled exosomes by LMECs was observed (Fig. 4B). In line with the in vivo data, ZFAS1 was downregulated in H/R-stimulated LMECs. BMSC-Exo treatment significantly enhanced ZFAS1 expression in H/R-exposed LMECs, which was counteracted by silencing of exosomal ZFAS1 but reinforced by the overexpression of exosomal ZFAS1 (Fig. 4C). Functional experiments demonstrated that H/R-induced decreased proliferation and migration capacities, and the apoptosis of LMECs could be restrained by BMSC-Exo administration (Fig. 4D–G). These BMSC-Exos-mediated changes were abolished by ZFAS1 inhibition, whereas ZFAS1 overexpression achieved opposite results (Fig. 4D–G). Similarly, BMSC-Exos repressed the release of inflammatory cytokines in H/R-exposed LMECs, which was inhibited by exosomal ZFAS1 depletion but intensified by exosomal ZFAS1 overexpression (Fig. 4H–J). Consistent with the in vivo results, FOXD1 and Gal-3 levels were increased in H/R-challenged LMECs, whereas BMSC-Exos effectively reduced the expression of these molecules (Fig. 4K). The regulatory effect of BMSC-Exos on FOXD1 and Gal-3 expression was abrogated by exosomal ZFAS1 knockdown and promoted by exosomal ZFAS1 overexpression (Fig. 4K). These results indicated that BMSC-Exos suppressed H/R-induced proliferation, migration inhibition, and apoptosis in LMECs via delivering ZFAS1.
FOXD1 Is Essential for ZFAS1-Mediated Biological Functions
Given that FOXD1 expression was modulated by BMSC-derived exosomal ZFAS1, we further investigated whether FOXD1 was involved in the biological function of exosomal ZFAS1. LMECs were infected with lentiviruses carrying shNC or shFOXD1. As shown in Fig. 5A and B, FOXD1 interference abolishes BMSC-derived exosomal ZFAS1 depletion-mediated proliferation inhibition in LMECs. In addition, the enhanced apoptosis and weakened migration of LMECs induced by ZFAS1 silencing in BMSC-Exos could be counteracted by FOXD1 suppression (Fig. 5C and D). Moreover, the downregulation of FOXD1 repressed the promotive effect of exosomal ZFAS1 depletion on inflammatory cytokine expression (Fig. 5E–G). Furthermore, the upregulation of FOXD1 and Gal-3 by exosomal ZFAS1 knockdown was reversed in FOXD1-silenced LMECs (Fig. 5H). Therefore, FOXD1 played a role in BMSC-derived exosomal ZFAS1-mediated biological functions in LMECs.
ZFAS1 Triggers the Destabilization of FOXD1 mRNA via Interacting with UPF1 in LMECs
We further explored the regulatory mechanism of ZFAS1 in FOXD1 expression in LMECs. RNA pull-down and RIP assays demonstrated a direct interaction between ZFAS1 and UPF1 in LMECs (Fig. 6A and B). Notably, UPF1 could also bind to FOXD1 based on the RIP assay (Fig. 6C). In addition, LMECs were infected with lentiviruses containing shNC or shUPF1, and we found that the depletion of UPF1 remarkably reduced UPF1 expression but increased FOXD1 expression in LMECs (Fig. 6D and E). The overexpression of ZFAS1 remarkably decreased FOXD1 expression, which was reversed by UPF1 knockdown (Fig. 6F and G). Furthermore, the interaction between UPF1 and FOXD1 in LMECs was weakened by ZFAS1 silencing (Fig. 6H). The stability of FOXD1 mRNA was reduced in ZFAS1-overexpressed LMECs, which could be restored by co-transfection with shUPF1 (Fig. 6I). These findings indicated that ZFAS1 could cause FOXD1 mRNA decay by directly interacting with UPF1.
FOXD1 Is a Transcriptional Factor of Gal-3
Next, we focused on the downstream modulatory mechanism of FOXD1. The luciferase activity of Gal-3 was reduced by the knockdown of FOXD1, whereas the overexpression of FOXD1 showed opposite effects (Fig. 7A). The ChIP assay further validated that FOXD1 directly bound to Gal-3 promotor (Fig. 7B). Moreover, LMECs were infected with lentiviruses carrying shNC, shFOXD1, vector, or FOXD1 overexpression plasmid. The results showed that the depletion of FOXD1 downregulated Gal-3, whereas the enforced expression of FOXD1 upregulated Gal-3 in LMECs (Fig. 7C and D). Collectively, FOXD1 directly bound to Gal-3 promotor and promoted the transcription and expression of Gal-3.
Knockdown of FOXD1 Represses H/R-Induced Injury in LMECs via Inhibiting Gal-3
We further examined whether FOXD1 affected H/R-induced injury in LMECs via regulating Gal-3. LMECs were infected with lentiviruses carrying shFOXD1 with or without the Gal3 gene. As presented in Fig. 8A and B, Gal-3 mRNA and protein levels are significantly increased in LMECs after infection with lentiviruses carrying the Gal3 gene. Moreover, the proliferation and migration were facilitated, whereas apoptosis in H/R-stimulated LMECs was repressed by FOXD1 depletion; however, these FOXD1 depletion-induced changes were abrogated by Gal-3 overexpression (Fig. 8C–F). Accordingly, the inhibitory effect of FOXD1 silencing on inflammatory response was attenuated by Gal-3 overexpression (Fig. 8G–I). Collectively, the knockdown of FOXD1 induced protection against H/R-induced injury in LMECs via suppressing Gal-3 expression.
BMSC-Derived Exosomal ZFAS1 Exerts Protection Against Pulmonary I/R Injury Through Regulating the FOXD1/Gal-3 Axis
Finally, the role of the FOXD1/Gal-3 axis in the beneficial effect of BMSC-derived exosomal ZFAS1 on pulmonary I/R injury was validated in vivo. The knockdown of exosomal ZFAS1 aggravated pathological changes in the lungs of pulmonary I/R mice, whereas the inhibition of FOXD1 or Gal-3 effectively attenuated lung I/R injury (Fig. 9A and B). In addition, pulmonary edema and apoptosis were promoted by exosomal ZFAS1 silencing, which were repressed after the downregulation of FOXD1 or Gal-3 in lung tissues (Fig. 9C and D). Consistently, the exosomal ZFAS1 depletion-mediated upregulation of MPO activity, MDA content, and inflammatory cytokine levels and the downregulation of SOD activity in lung tissues were all counteracted in FOXD1- or Gal-3-silenced groups (Fig. 9E–J). Western blotting showed that FOXD1 and Gal-3 levels were increased by treatment with ZFAS1-depleted BMSC-Exos; however, these changes were abolished by FOXD1 or Gal-3 knockdown (Fig. 9K). Collectively, BMSC-derived exosomal ZFAS1 relieved in vivo pulmonary I/R injury via modulating the FOXD1/Gal-3 axis.
Discussion
Pulmonary I/R injury remains a major cause of poor prognosis and high mortality after lung transplantation [26]. Therefore, developing novel effective therapeutic approaches is necessary to delay the progression of pulmonary I/R injury. Recently, BMSC-Exos have been recognized as a therapeutic option for pulmonary I/R injury [9]. However, its potential protective mechanism remains unclear; thus, more studies must be conducted. In this study, we found that lncRNA ZFAS1 delivered by BMSC-Exos alleviated pulmonary I/R injury through UPF1-mediated FOXD1 mRNA decay and subsequent inactivation of Gal-3. Our data provided insights into the molecular mechanism through which BMSC-Exos attenuated pulmonary I/R injury.
Growing evidence has indicated that MSCs derived from various tissues are conducive to tissue repair, regeneration, and inflammation inhibition through an exosome-mediated paracrine effect [27]. Functional proteins and nucleotides (including lncRNAs and miRNAs) can be carried by exosomes and then taken up by receptor cells, thereby affecting the transduction of multiple signaling pathways [28]. According to Chen et al., BMSC-Exos induced protection against myocardial I/R injury via delivering miR-125b [29]. With regard to pulmonary I/R injury, MSC-Exos played anti-inflammatory and anti-apoptotic roles in lung tissues during pulmonary I/R injury via transporting miR-21-5p [9]. Consistent with previous observations, we demonstrated that BMSC-Exo administration improved pathological changes in the lungs, edema, inflammatory response, and apoptosis in the mouse model of lung I/R injury and inhibited H/R-triggered lung epithelial cell inflammation and apoptosis in vitro. Interestingly, BMSC-Exos enhanced ZFAS1 expression in lungs, indicating that BMSC-Exos induced beneficial effects via the transportation of ZFAS1.
In addition, the inhibitory role of ZFAS1 in apoptosis and inflammation during cerebral I/R injury has been reported [30], although the influence of ZFAS1 on pulmonary I/R injury remains unknown. Notably, ZFAS1 has been documented to alleviate sepsis-induced lung injury via repressing inflammation and apoptosis [15]. In our report, silencing of exosomal ZFAS1 abrogated the beneficial effect of MSC-Exos on pulmonary I/R injury in vivo and in vitro, providing the first evidence that BMSC-Exos induced protection against pulmonary I/R injury via delivering ZFAS1.
Extensive research has suggested that lncRNAs can modulate gene transcription via interaction with RBPs [31]. As an RBP, UPF1 has been recognized as a regulator of the mRNA degradation pathway [32]. Based on previous reports, lncRNA zinc finger protein multitype 2 antisense RNA 1 (ZFPM2-AS1) interacted with UPF1 to trigger the degradation of ZFPM2, which accelerated lung adenocarcinoma progression [33]. In this work, UPF1 was considered as an RBP of ZFAS1. Further experiments revealed that ZFAS1 destabilized FOXD1 mRNA via interaction with UPF1 in LMECs. FOXD1 is a member of the forkhead box transcription factor family, which participates in various pathophysiologic processes, including embryogenesis, metabolism, cell cycle, and apoptosis modulation [34]. For example, FOXD1 could affect the occurrence and progression of a variety of tumors [35, 36]. Based on a previous study, FOXD1 modulated inflammatory reactions and prevented autoimmunity via the NF-kappaB/NFAT pathway [37]. Notably, FOXD1 has been shown to play a role in renal I/R injury [38]. These observations indicated the close association of FOXD1 with inflammation and I/R injury. In the present study, the knockdown of FOXD1 reversed the promotive role of exosomal ZFAS1 downregulation in H/R-induced injury, indicating that the UPF1-mediated degradation of FOXD1 was involved in the beneficial mechanism of BMSC-derived exosomal ZFAS1.
Gal-3, a pleiotropic β-galactoside-binding lectin, has been considered as a master regulator of multiple biological processes, including proliferation, inflammation, apoptosis, and immunoregulation [39,40,41]. Based on previous reports, Gal-3 was responsible for ozone-induced lung injury via facilitating the accumulation of pro-inflammatory macrophages [42]. To date, the involvement of Gal-3 in pulmonary I/R injury has not been well-understood. According to Li et al., FOXD1 and Gal-3 reciprocally regulated each other during lung cancer development [19]. In the current work, FOXD1 bound to the Gal-3 promoter, thereby promoting the transcription and expression of Gal-3 in LMECs. The overexpression of Gal-3 hindered the beneficial effect of FOXD1 depletion on H/R-induced injury in LMECs. For the first time, these findings highlighted that the FOXD1/Gal-3 axis served as a pivotal contributor to pulmonary I/R injury.
This study had several limitations. First, intratracheal administration was applied in mice in this study. However, the implementation of endotracheal intubation in clinical practice is limited because of lack of experienced airway providers in many rural and remote settings [43]. Therefore, intratracheal administration may not be a simple and appropriate delivery route in patients. Second, we selected single administration of BMSC-Exos in mice with pulmonary I/R injury. However, the efficacy of repeated administration and the long-term efficacy of BMSC-Exos remain unclear. Thus, determining the suitable administration of BMSC-Exos must be further investigated.
Our data indicated that BMSC-derived exosomal ZFAS1 relieved pulmonary I/R injury by directly interacting with UPF1 to destabilize FOXD1 and subsequently inactivating the Gal-3 pathway, which uncovered the underlying protective mechanism of BMSC-Exos. Our results provided theoretical evidence for the application of exosomal ZFAS1 derived from BMSC-Exos in the clinical treatment of pulmonary I/R injury.
Availability of Data and Material
All data generated or analyzed during this study are included in this published article.
Abbreviations
- ANOVA:
-
Analysis of variance
- BMSC-Exos:
-
BMSC-derived exosomes
- BMSCs:
-
Bone marrow-derived MSCs
- CCK-8:
-
Cell counting kit 8
- ChIP:
-
Chromatin immunoprecipitation
- DAPI:
-
4′-6-Diamidino-2-phenylindole
- EdU:
-
5-Ethynyl-2′-deoxyuridine
- FBS:
-
Fetal bovine serum
- FOXD1:
-
Forkhead box D1
- Gal-3:
-
Galectin-3
- H&E:
-
Hematoxylin and eosin
- HLA-DR:
-
Human leukocyte antigen DR
- H/R:
-
Hypoxia/reoxygenation
- Hsp70:
-
Heat shock protein
- I/R:
-
Ischemia/reperfusion
- LMECs:
-
Lung microvascular endothelial cells
- lncRNAs:
-
Long non-coding RNAs
- MEG3:
-
Maternally expressed gene 3
- MSCs:
-
Mesenchymal stem cells
- NTA:
-
Nanoparticle tracking analysis
- PBS:
-
Phosphate-buffered saline
- PTBP1:
-
Polypyrimidine tract-binding protein 1
- qRT-PCR:
-
Quantitative real-time PCR
- RBPs:
-
RNA-binding proteins
- RIP:
-
RNA immunoprecipitation
- shNC:
-
Negative control shRNA
- TSG101:
-
Tumor susceptibility gene 101
- TUNEL:
-
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling
- UPF1:
-
Up-frameshift 1
- W/D:
-
Wet/dry
- XIST:
-
X-inactive-specific transcript
- ZFAS1:
-
Zinc finger antisense 1
- ZFPM2-AS1:
-
Zinc finger protein multitype 2 antisense RNA 1
References
den Hengst WA, Gielis JF, Lin JY, Van Schil PE, De Windt LJ, Moens AL (2010) Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol 299(5):H1283-1299. https://doi.org/10.1152/ajpheart.00251.2010
Porteous MK, Diamond JM, Christie JD (2015) Primary graft dysfunction: lessons learned about the first 72 h after lung transplantation. Curr Opin Organ Transplant 20(5):506–514. https://doi.org/10.1097/MOT.0000000000000232
Pak O, Sydykov A, Kosanovic D, Schermuly RT, Dietrich A, Schroder K, Brandes RP, Gudermann T, Sommer N, Weissmann N (2017) Lung ischaemia-reperfusion injury: the role of reactive oxygen species. Adv Exp Med Biol 967:195–225. https://doi.org/10.1007/978-3-319-63245-2_12
Laubach VE, Sharma AK (2016) Mechanisms of lung ischemia-reperfusion injury. Curr Opin Organ Transplant 21(3):246–252. https://doi.org/10.1097/MOT.0000000000000304
Nakajima D, Watanabe Y, Ohsumi A, Pipkin M, Chen M, Mordant P, Kanou T, Saito T, Lam R, Coutinho R, Caldarone L, Juvet S, Martinu T, Iyer RK, Davies JE, Hwang DM, Waddell TK, Cypel M, Liu M, Keshavjee S (2019) Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 38(11):1214–1223. https://doi.org/10.1016/j.healun.2019.07.006
Podesta MA, Remuzzi G, Casiraghi F (2020) Mesenchymal stromal cell therapy in solid organ transplantation. Front Immunol 11:618243. https://doi.org/10.3389/fimmu.2020.618243
Lazar E, Benedek T, Korodi S, Rat N, Lo J, Benedek I (2018) Stem cell-derived exosomes - an emerging tool for myocardial regeneration. World J Stem Cells 10(8):106–115. https://doi.org/10.4252/wjsc.v10.i8.106
Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200(4):373–383. https://doi.org/10.1083/jcb.201211138
Li JW, Wei L, Han Z, Chen Z (2019) Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p. Eur J Pharmacol 852:68–76. https://doi.org/10.1016/j.ejphar.2019.01.022
Massa M, Croce S, Campanelli R, Abba C, Lenta E, Valsecchi C, Avanzini MA (2020) Clinical applications of mesenchymal stem/stromal cell derived extracellular vesicles: therapeutic potential of an acellular product. Diagnostics (Basel) 10(12):E999. https://doi.org/10.3390/diagnostics10120999
Quinn JJ, Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17(1):47–62. https://doi.org/10.1038/nrg.2015.10
Statello L, Guo CJ, Chen LL, Huarte M (2021) Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 22(2):96–118. https://doi.org/10.1038/s41580-020-00315-9
Yao RW, Wang Y, Chen LL (2019) Cellular functions of long noncoding RNAs. Nat Cell Biol 21(5):542–551. https://doi.org/10.1038/s41556-019-0311-8
Li J, Wei L, Han Z, Chen Z, Zhang Q (2020) Long non-coding RNA X-inactive specific transcript silencing ameliorates primary graft dysfunction following lung transplantation through microRNA-21-dependent mechanism. EBioMedicine 52:102600. https://doi.org/10.1016/j.ebiom.2019.102600
Jiang Y, Zhang W (2021) LncRNA ZFAS1 plays a role in regulating the inflammatory responses in sepsis-induced acute lung injury via mediating miR-193a-3p. Infect Genet Evol 92:104860. https://doi.org/10.1016/j.meegid.2021.104860
Pan L, Liang W, Fu M, Huang ZH, Li X, Zhang W, Zhang P, Qian H, Jiang PC, Xu WR, Zhang X (2017) Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol 143(6):991–1004. https://doi.org/10.1007/s00432-017-2361-2
Zhang L, Yang Z, Trottier J, Barbier O, Wang L (2017) Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay. Hepatology 65(2):604–615. https://doi.org/10.1002/hep.28882
Azzalin CM, Lingner J (2006) The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. Curr Biol 16(4):433–439. https://doi.org/10.1016/j.cub.2006.01.018
Li CH, Chang YC, Hsiao M, Liang SM (2019) FOXD1 and Gal-3 form a positive regulatory loop to regulate lung cancer aggressiveness. Cancers (Basel) 11(12):E1897. https://doi.org/10.3390/cancers11121897
Eslaminejad MB, Nadri S (2009) Murine mesenchymal stem cell isolated and expanded in low and high density culture system: surface antigen expression and osteogenic culture mineralization. In Vitro Cell Dev Biol Anim 45(8):451–459. https://doi.org/10.1007/s11626-009-9198-1
Zeng Q, Zhou Y, Liang D, He H, Liu X, Zhu R, Zhang M, Luo X, Wang Y, Huang G (2020) Exosomes secreted from bone marrow mesenchymal stem cells attenuate oxygen-glucose deprivation/reoxygenation-induced pyroptosis in PC12 cells by promoting AMPK-dependent autophagic flux. Front Cell Neurosci 14:182. https://doi.org/10.3389/fncel.2020.00182
Stephens RS, Rentsendorj O, Servinsky LE, Moldobaeva A, Damico R, Pearse DB (2010) cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 299(3):L323-333. https://doi.org/10.1152/ajplung.00442.2009
Sharma AK, Charles EJ, Zhao Y, Narahari AK, Baderdinni PK, Good ME, Lorenz UM, Kron IL, Bayliss DA, Ravichandran KS, Isakson BE, Laubach VE (2018) Pannexin-1 channels on endothelial cells mediate vascular inflammation during lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 315(2):L301–L312. https://doi.org/10.1152/ajplung.00004.2018
Xu Y, Li X, Cheng Y, Yang M, Wang R (2020) Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion. FASEB J 34(12):16262–16275. https://doi.org/10.1096/fj.202001758R
Wang M, Ji P, Wang R, Zhao L, Xia Z (2012) TRPV1 agonist capsaicin attenuates lung ischemia-reperfusion injury in rabbits. J Surg Res 173(1):153–160. https://doi.org/10.1016/j.jss.2010.08.053
Luo N, Liu J, Chen Y, Li H, Hu Z, Abbott GW (2018) Remote ischemic preconditioning STAT3-dependently ameliorates pulmonary ischemia/reperfusion injury. PLoS One 13(5):e0196186. https://doi.org/10.1371/journal.pone.0196186
Silva AM, Teixeira JH, Almeida MI, Goncalves RM, Barbosa MA, Santos SG (2017) Extracellular Vesicles: Immunomodulatory messengers in the context of tissue repair/regeneration. Eur J Pharm Sci 98:86–95. https://doi.org/10.1016/j.ejps.2016.09.017
Dong H, Wang W, Chen R, Zhang Y, Zou K, Ye M, He X, Zhang F, Han J (2018) Exosome-mediated transfer of lncRNASNHG14 promotes trastuzumab chemoresistance in breast cancer. Int J Oncol 53(3):1013–1026. https://doi.org/10.3892/ijo.2018.4467
Chen Q, Liu Y, Ding X, Li Q, Qiu F, Wang M, Shen Z, Zheng H, Fu G (2020) Bone marrow mesenchymal stem cell-secreted exosomes carrying microRNA-125b protect against myocardial ischemia reperfusion injury via targeting SIRT7. Mol Cell Biochem 465(1–2):103–114. https://doi.org/10.1007/s11010-019-03671-z
Zhang Y (2020) lncRNA ZFAS1 improves neuronal injury and inhibits inflammation, oxidative stress, and apoptosis by sponging miR-582 and upregulating NOS3 expression in cerebral ischemia/reperfusion injury. Inflammation 43(4):1337–1350. https://doi.org/10.1007/s10753-020-01212-1
Janakiraman H, House RP, Gangaraju VK, Diehl JA, Howe PH, Palanisamy V (2018) The Long (lncRNA) and short (miRNA) of It: TGFbeta-mediated control of RNA-binding proteins and noncoding RNAs. Mol Cancer Res 16(4):567–579. https://doi.org/10.1158/1541-7786.MCR-17-0547
Dehecq M, Decourty L, Namane A, Proux C, Kanaan J, Le Hir H, Jacquier A, Saveanu C (2018) Nonsense-mediated mRNA decay involves two distinct Upf1-bound complexes. EMBO J 37 (21). e99278 https://doi.org/10.15252/embj.201899278
Han S, Cao D, Sha J, Zhu X, Chen D (2020) LncRNA ZFPM2-AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2. Mol Oncol 14(5):1074–1088. https://doi.org/10.1002/1878-0261.12631
Hannenhalli S, Kaestner KH (2009) The evolution of Fox genes and their role in development and disease. Nat Rev Genet 10(4):233–240. https://doi.org/10.1038/nrg2523
Mu L, Zhang J, Wu Z, Huang J, Cui Y (2022) FOXD1 Regulates the sensitivity of cetuximab by regulating the expression of EGFR in head and neck squamous cell cancer. J Healthc Eng 2022:6108241. https://doi.org/10.1155/2022/6108241
Bond KH, Fetting JL, Lary CW, Emery IF, Oxburgh L (2021) FOXD1 regulates cell division in clear cell renal cell carcinoma. BMC Cancer 21(1):312. https://doi.org/10.1186/s12885-021-07957-8
Lin L, Peng SL (2006) Coordination of NF-kappaB and NFAT antagonism by the forkhead transcription factor Foxd1. J Immunol 176(8):4793–4803. https://doi.org/10.4049/jimmunol.176.8.4793
Meng F, Liu Y, Chen Q, Ma Q, Gu S, Cui R, Cao R, Zhao M (2020) METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation. Am J Physiol Renal Physiol 319(5):F839–F847. https://doi.org/10.1152/ajprenal.00222.2020
Perillo NL, Marcus ME, Baum LG (1998) Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med (Berl) 76(6):402–412. https://doi.org/10.1007/s001090050232
Liu FT (2005) Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol 136(4):385–400. https://doi.org/10.1159/000084545
Liu FT, Hsu DK (2007) The role of galectin-3 in promotion of the inflammatory response. Drug News Perspect 20(7):455–460. https://doi.org/10.1358/dnp.2007.20.7.1149628
Sunil VR, Francis M, Vayas KN, Cervelli JA, Choi H, Laskin JD, Laskin DL (2015) Regulation of ozone-induced lung inflammation and injury by the beta-galactoside-binding lectin galectin-3. Toxicol Appl Pharmacol 284(2):236–245. https://doi.org/10.1016/j.taap.2015.02.002
Levin BS, Chang MG, Bittner EA (2021) Teleguidance technology for endotracheal intubation: a scoping review. Crit Care Explor 3(12):e0582. https://doi.org/10.1097/CCE.0000000000000582
Acknowledgements
We would like to give our sincere gratitude to the reviewers for their constructive comments.
Funding
This work was supported in part by Changzhou HighLevel Medical Talents Training Project (KY20221373 and KY20221357) and the Major Program of Science and Technology Project of Changzhou Health Commission (ZD202206).
Author information
Authors and Affiliations
Contributions
Cao Gao: Conceptualization, Writing-original draft preparation, Investigation, Validation, Visualization, Methodology.
Yan-Jie Xu: Software.
Zhi-xiu Meng: Methodology.
Shuang Gu: Data curation.
Lei Zhang: Visualization.
Liang Zheng: Conceptualization, Writing-original draft preparation, Supervision, Writing-reviewing and editing.
Corresponding author
Ethics declarations
Ethics Approval and Consent to Participate
The lungs were harvested after euthanasia by overdose of sodium pentobarbital. All procedures were approved by the Animal Care and Use Committee of the Third Affiliated Hospital of Soochow University.
Consent for Publication
The informed consent obtained from study participants.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gao, C., Xu, YJ., Meng, Zx. et al. BMSC-Derived Exosomes Carrying lncRNA-ZFAS1 Alleviate Pulmonary Ischemia/Reperfusion Injury by UPF1-Mediated mRNA Decay of FOXD1. Mol Neurobiol 60, 2379–2396 (2023). https://doi.org/10.1007/s12035-022-03129-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-022-03129-2